Diane Dahowski - 01 Sep 2023 Form 4 Insider Report for BIO-RAD LABORATORIES, INC. (BIO)

Reporting relationship: EVP, Global Supply Chain
Issuer ticker: BIO
Reported as of: 01 Sep 2023
Net transaction value: -$341,724
SEC form: 4
Accepted by SEC: 06 Sep 2023, 12:56:20 UTC
Prior SEC filing: 07 Sep 2022
Source filing: View source filing
Reporting owner signature: /s/ Diane Dahowski

Filing notes and source

Key filing fact

Diane Dahowski filed Form 4 for BIO-RAD LABORATORIES, INC. (BIO) on 06 Sep 2023.

Key facts

This page summarizes Diane Dahowski's Form 4 filing for BIO-RAD LABORATORIES, INC. (BIO).
15 reported transactions and 5 derivative rows are listed below.
Accepted by SEC: 06 Sep 2023, 12:56.

Change

Previous filing in this sequence was filed on 07 Sep 2022.
Current net transaction value: -$341,724.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

BIO transaction

Bio-Rad A Common Stock

Options Exercise

Transaction value: $0
Shares: +520
Change %: +5%
Price: $0.000000
Shares after: 10,961
Date: 01 Sep 2023
Ownership: Direct
Footnotes: F1, F2

BIO transaction

Bio-Rad A Common Stock

Tax liability

Transaction value: -$71,028
Shares: -180
Change %: -1.6%
Price: $394.60
Shares after: 10,781
Date: 01 Sep 2023
Ownership: Direct

BIO transaction

Bio-Rad A Common Stock

Options Exercise

Transaction value: $0
Shares: +329
Change %: +3.1%
Price: $0.000000
Shares after: 11,110
Date: 01 Sep 2023
Ownership: Direct
Footnotes: F1

BIO transaction

Bio-Rad A Common Stock

Tax liability

Transaction value: -$44,984
Shares: -114
Change %: -1%
Price: $394.60
Shares after: 10,996
Date: 01 Sep 2023
Ownership: Direct

BIO transaction

Bio-Rad A Common Stock

Options Exercise

Transaction value: $0
Shares: +361
Change %: +3.3%
Price: $0.000000
Shares after: 11,357
Date: 02 Sep 2023
Ownership: Direct
Footnotes: F1

BIO transaction

Bio-Rad A Common Stock

Tax liability

Transaction value: -$49,325
Shares: -125
Change %: -1.1%
Price: $394.60
Shares after: 11,232
Date: 02 Sep 2023
Ownership: Direct

BIO transaction

Bio-Rad A Common Stock

Options Exercise

Transaction value: $0
Shares: +495
Change %: +4.4%
Price: $0.000000
Shares after: 11,727
Date: 03 Sep 2023
Ownership: Direct
Footnotes: F1

BIO transaction

Bio-Rad A Common Stock

Tax liability

Transaction value: -$67,871
Shares: -172
Change %: -1.5%
Price: $394.60
Shares after: 11,555
Date: 03 Sep 2023
Ownership: Direct

BIO transaction

Bio-Rad A Common Stock

Options Exercise

Transaction value: $0
Shares: +600
Change %: +5.2%
Price: $0.000000
Shares after: 12,155
Date: 04 Sep 2023
Ownership: Direct
Footnotes: F1

BIO transaction

Bio-Rad A Common Stock

Tax liability

Transaction value: -$108,515
Shares: -275
Change %: -2.3%
Price: $394.60
Shares after: 11,880
Date: 04 Sep 2023
Ownership: Direct

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

BIO transaction Derivative

Restricted Stock Units

Options Exercise

Transaction value: $0
Shares: -520
Change %: -25%
Price: $0.000000
Shares after: 1,562
Date: 01 Sep 2023
Ownership: Direct
Underlying class: Bio-Rad A Common Stock
Underlying amount: 520
Exercise price: $0.000000
Footnotes: F3, F4

BIO transaction Derivative

Restricted Stock Units

Options Exercise

Transaction value: $0
Shares: -329
Change %: -33%
Price: $0.000000
Shares after: 659
Date: 01 Sep 2023
Ownership: Direct
Underlying class: Bio-Rad A Common Stock
Underlying amount: 329
Exercise price: $0.000000
Footnotes: F3, F5

BIO transaction Derivative

Restricted Stock Units

Options Exercise

Transaction value: $0
Shares: -361
Change %: -50%
Price: $0.000000
Shares after: 361
Date: 02 Sep 2023
Ownership: Direct
Underlying class: Bio-Rad A Common Stock
Underlying amount: 361
Exercise price: $0.000000
Footnotes: F3, F6

BIO transaction Derivative

Restricted Stock Units

Options Exercise

Transaction value: $0
Shares: -495
Change %: -50%
Price: $0.000000
Shares after: 495
Date: 03 Sep 2023
Ownership: Direct
Underlying class: Bio-Rad A Common Stock
Underlying amount: 495
Exercise price: $0.000000
Footnotes: F3, F7

BIO transaction Derivative

Restricted Stock Units

Options Exercise

Transaction value: $0
Shares: -600
Change %: -100%
Price: $0.000000^*
Shares after: 0
Date: 04 Sep 2023
Ownership: Direct
Underlying class: Bio-Rad A Common Stock
Underlying amount: 600
Exercise price: $0.000000
Footnotes: F3, F8

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 8 footnotes

Footnote F1

Shares of Class A common stock acquired on the vesting of restricted stock units.

Footnote F2

Includes 31.8970 and 24.7960 shares acquired under the Bio-Rad Employee Stock Purchase Plan on 03/31/2023 and 06/30/2023.

Footnote F3

Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock.

Footnote F4

On September 1, 2022, the reporting person was granted 2,082 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date.

Footnote F5

On September 1, 2021, the reporting person was granted 1,317 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date.

Footnote F6

On September 2, 2020, the reporting person was granted 1,444 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date.

Footnote F7

On September 3, 2019, the reporting person was granted 2,475 restricted stock units, vesting in five equal annual installments beginning on the first anniversary of the grant date.

Footnote F8

On September 4, 2018, the reporting person was granted 3,000 restricted stock units, vesting in five equal annual installments beginning on the first anniversary of the grant date.